GDRXNasdaqServices-Computer Processing & Data PreparationUS GAAP · USD

GoodRx Holdings, Inc.

GoodRx Holdings, Inc. operates a consumer healthcare platform that helps Americans compare prescription prices, access discount pricing, and manage medication affordability. The company monetizes traffic through prescription transaction fees, subscription offerings, and pharma manufacturer solutions, while also expanding into telehealth and other healthcare services.

Revenue797m USD
+0.6 %y/y
Operating profit (EBIT)87.5m USD
+32.9 %y/y
EBIT margin11.0%
+2.7 ppy/y
Net income30.4m USD
+85.7 %y/y
Free cash flow164m USD
−10.0 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-500-25002505007501,000m USD2020: 551 m USD2020: EBIT -276 m USD20202021: 745 m USD2021: EBIT 13 m USD20212022: 767 m USD2022: EBIT 1.7 m USD20222023: 750 m USD2023: EBIT -27 m USD20232024: 792 m USD2024: EBIT 66 m USD20242025: 797 m USD2025: EBIT 87 m USD202579787
RevenueOperating profit (EBIT)

Business

Share of revenue
Prescription transactions72 %

Consumer prescription pricing, discount codes, and transaction-based savings at pharmacies.

Subscription services10 %

Paid consumer plans such as GoodRx Gold that provide enhanced medication savings.

Pharma manufacturer solutions18 %

Commercial services for drug makers, including patient access and affordability programs.

Products

Reported · share of revenue
68.3%19.0%10.5%FY2025100 %
  • Prescription Transactions Revenue68.3 %
  • Pharma Direct Revenue19.0 %
  • Subscription Revenue10.5 %
  • Other Revenue2.2 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

GoodRx sells to consumers seeking lower out-of-pocket prescription costs, but its commercial relationships also span pharmacies, PBMs, and pharmaceutical manufacturers. Consumers use the platform for price transparency and savings, while partners use it to drive volume, improve adherence, and reach patients more efficiently.

Consumers

Individuals using GoodRx to compare prices, access discount codes, and save on prescriptions.

Pharmacy Benefit Managers (PBMs)

PBMs provide cash-network pricing and discounts that GoodRx routes to consumers to generate transactions.

Retail pharmacies

Pharmacies partner with GoodRx to reduce walk-away patients and increase prescription volume.

Pharmaceutical manufacturers

Drug makers buy access and affordability solutions to support patient uptake and adherence.

Healthcare providers and telehealth users

Providers and patients use adjacent digital tools and telehealth offerings tied to the platform.

Strategy

GoodRx is focused on expanding from prescription savings into a broader consumer healthcare platform while increasing monetization from its existing user base. Management is also emphasizing strategic partnerships, deeper pharmacy relationships, and selective acquisitions to strengthen distribution and improve unit economics.

Expand multi-product adoptionMedium term

Using more offerings per consumer raises lifetime value without proportionate acquisition cost.

Strengthen partner ecosystemMedium term

PBMs, pharmacies, and manufacturers are core to pricing, traffic, and monetization.

Grow pharma manufacturer solutionsShort term

This segment is growing faster and can diversify revenue away from consumer transaction dependence.

Improve brand awarenessLong term

Awareness is a key barrier to adoption in a consumer healthcare market with many alternatives.

Geography

GoodRx generates all of its revenue in the United States, and its platform is built around U.S. prescription pricing, pharmacy networks, and healthcare rules. This makes the business highly exposed to U.S. retail pharmacy dynamics, PBM contracting, and federal and state healthcare policy changes.

Risks

GoodRx depends on a limited set of PBMs, pharmacies, and transaction-processing vendors, so partner concentration and contract changes can quickly affect pricing and revenue. The company is also exposed to U.S. healthcare regulation, retail pharmacy disruption, and competition for consumer attention, all of which can reduce transaction volume or weaken its value proposition.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Retail pharmacy disruption1PBM and partner concentration2U.S. healthcare regulation3Competition and consumer awareness4Platform and cybersecurity risk5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Retail pharmacy disruptionImpact: HighLikelihood: Medium

    Store closures and volume declines reduce prescription transactions processed through the platform.

    Exposure: Broader retail pharmacy landscape changes

  2. PBM and partner concentrationImpact: HighLikelihood: Low

    A limited number of PBMs generate a significant portion of discounted prices and revenue.

    Exposure: Three largest PBM customers accounted for 22% of revenue in 2025

  3. U.S. healthcare regulationImpact: MediumLikelihood: Medium

    Federal and state changes to healthcare spending and medication pricing can alter the economics of the platform.

    Exposure: Prescription affordability and pricing transparency business model

  4. Competition and consumer awarenessImpact: MediumLikelihood: Medium

    The company says awareness is a primary barrier to adoption, so rivals can limit growth.

    Exposure: Consumer internet and healthcare savings tools

  5. Platform and cybersecurity riskImpact: MediumLikelihood: Medium

    The business relies on apps, websites, pricing data, and transaction processing infrastructure.

    Exposure: Digital healthcare platform operations

Accounting

Judgemental items
Revenue recognition by stream

Different revenue lines have different timing and drivers, so mix changes affect comparability.

Impact: Prescription transactions, subscriptions, and pharma manufacturer solutions

Subscription churn and plan sunsets

Changes in subscription plan counts directly affect recurring revenue and growth rates.

Impact: GoodRx Gold and other subscription offerings

Business combination accounting

Acquisitions can add intangible assets, goodwill, and integration-related costs.

Impact: VCRx acquisition and future strategic acquisitions

Capitalized software development

Platform investment affects operating expense timing and asset balances.

Impact: Product development and technology spending

Debt and restricted net assets

Holding company status and debt covenants limit upstream distributions and dividend capacity.

Impact: Parent company liquidity and capital allocation

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026